I became Morgan Stanley in Kaken Pharmaceutical Co Ltd (4521:JP)’s corporate disclosure and got an “overweight” rating with a price of ¥6,100. The investment bank’s analysis was carried out recently, in February 2025, as part of the exclusive investment projects for Kakens’ key products, Australian companies and investment companies in the innovation sector innovative people have made their decision.

The analyst pledged Clenafin’s patent price to be 1.06 times higher than the current purchase price. The Fokus verlagere sich nonn auf Kakens Potenzial als Wachstumsunternehmen im Pharmasektor, base auf seiner Pipeline new Medikamente.

Now the launch of Clenafin takes place at the end of the year when it comes to investment. During 2020, a development program created a new portfolio creation strategy within the innovative portfolio layout. The analyst predicts the two new drugs from Kaken until the expiration of the market 2027 and the advancers of the Wachstumstreibern can compensate the arrival of the patents of Clenafin.

The optimistic approach applies to analysts’ predictions, for the March 31 study, a $12 billion valuation by two new upcoming drugs.

These medications are aufgrund vielversprechender clinicischer Daten et Studiendesigns als highgradig erfolgversprechend eingestuft, wobei eines bereits in den Vereinigten Staaten zugelassen ist. Zum Vergleich: Der Betriebsgewinn im Geschäftsjahr zum Marz 2024 belief sich auf 9.5 Billion ¥.

Morgan Stanley’s analysis reports Kaken Pharmaceuticals Fähigkeit recommendations, recommendations for the best and potential nutrient base drugs.

This Übersetzung wurde mithilfe künstlicher Intelligenz erstellt. Please note that further information is required to provide additional information.